Emv Capital (EMVC)

Sector:

Financials

46.50p
   
  • Change Today:
    -1.50p
  • 52 Week High: 76.50
  • 52 Week Low: 44.00
  • Currency: UK Pounds
  • Shares Issued: 24.36m
  • Volume: 9,279
  • Market Cap: £11.33m
  • Beta: 0.32

Deal with Barclays    Trade now with Barclays Stockbrokers

NetScientific's PDS investment begins phase 2 trial of cancer treatment

By Josh White

Date: Tuesday 27 Oct 2020

LONDON (ShareCast) - (Sharecast News) - Life sciences and technology investor NetScientific announced on Tuesday that its portfolio company PDS Biotechnology has opened the phase 2 clinical trial of 'PDS0101' in combination with standard of care chemoradiotherapy, for the treatment of locally-advanced cervical cancer.

The AIM-traded firm said the trial was being led by Ann Klopp, associate professor of radiation oncology and Olsi Gjyshi, resident in radiation oncology at the University of Texas MD Anderson Cancer Center.

It said the trial would investigate the antitumour efficacy and safety of the PDS0101-chemoradiotherapy combination, and its correlation with critical biomarkers of immune response, in about 35 patients.

"In line with NetScientific's strategic review and stated plans, we supported PDS through two successful public placements approximating $32m in 2020," said Dr Ilian Iliev, chief executive officer of NetScientific and a director of PDS Biotechnology.

"The resulting funding provided PDS with the resources and runway needed to implement their ambitions development programme.

"We are pleased at the continued progress of PDS in reaching the start of this phase 2 clinical trial with a prestigious partner."

NetScientific holds around 5.75% of the undiluted share capital in PDS Biotechnology.

At 1258 GMT, shares in NetScientific were up 3.45% at 58.45p.

Email this article to a friend

or share it with one of these popular networks:


Note 1: Prices and trades are provided by Digital Look Corporate Solutions and are delayed by at least 15 minutes.

 

Emv Capital Market Data

Currency UK Pounds
Share Price 46.50p
Change Today -1.50p
% Change -3.13 %
52 Week High 76.50
52 Week Low 44.00
Volume 9,279
Shares Issued 24.36m
Market Cap £11.33m
Beta 0.32

Emv Capital Star Ratings

Compare performance with the sector and the market.
more star ratings
Key: vs Market vs Sector
Value Not Available
Price Trend
59.88% below the market average59.88% below the market average59.88% below the market average59.88% below the market average59.88% below the market average
67.86% below the sector average67.86% below the sector average67.86% below the sector average67.86% below the sector average67.86% below the sector average
Income Not Available
Growth Not Available

Emv Capital Dividends

No dividends found

Trades for 21-Nov-2024

Time Volume / Share Price
14:00 150 @ 49.00p
14:00 150 @ 49.00p
12:16 2,311 @ 45.24p
12:15 5,769 @ 47.10p
08:21 1,049 @ 47.68p

Emv Capital Key Personnel

CEO Ilian Iliev
CFO Stephen Crowe

Top of Page